The global Crohn’s disease market is slated to register 3.3% CAGR over the forecast period, 2019 to 2025.
The numerous drug advances for Crohn’s disease management are proving helpful to the industry. Furthermore, changing diets that have culminated in the substitution of healthier eating patterns with unhealthy ones, as well as an uptick in smoking, have resulted in a rise in the number of people living with Crohn’s disease, fueling further consumer development. In addition, the demand for biologics to treat bowel disorders, such as Crohn’s disease, as well as increased understanding of the disease and current therapies, are fueling the market. To retain their market share, some firms and producers are working with other players to create innovative strategies for new product releases and promotion of existing drugs.
As a result, core developments in the Crohn’s disease industry, such as increased preference for symptomatic medications and therapeutics over procedures, advanced disease control for inflammatory bowel diseases like Crohn’s disease, and the introduction of improved drugs in the market owing to increased expenditures in R&D projects, are expected to dominate the market. The high cost of medication, on the other hand, is expected to be a significant business constraint. Furthermore, lack of early detection, especially in developing countries, and the expiration of patents on blockbuster drugs may stymie market expansion in the immediate future.
Costly insurance plans and a lack of early recognition due to a lack of knowledge of the condition are two factors that could limit the development of the Crohn’s disease industry.
The global Crohn’s disease market has been segmented based type, treatment, end user, and region.
The global market, based on type, has been segmented into ileocolitis, ileitis, granulomatous colitis, gastroduodenal Crohn’s disease, jejunoileitis, and perianal Crohn’s disease.
Based on the treatment, the market is further divided into non-surgical and surgical.
Based on end user, the global market is segment into hospitals & clinics, research institutes, diagnostic centers, and others. According to the delivery channel segment, the hospital pharmacy sub-segment added the most to the Crohn’s business during the prediction era. The rising number of in-patients and out-patients with Crohn’s disease, as well as many hospitals dealing with the disease, has raised demand for Crohn’s disease drugs.
Based on treatment, Thanks to its superior potency relative to analgesics and immunosuppressants, the anti-inflammatory segment was the largest segment of the industry in 2018, while the immune system suppressors segment is projected to be the fastest-growing segment due to lower surgery and hospitalisation rates.
The key players operating in the global Crohn’s disease market are Johnson & Johnson Services Inc., Pfizer Inc., Allergan, AbbVie Inc, Bayer AG, Amgen, Inc., Takeda Pharmaceutical Company Limited, UCB S.A., Ferring B.V., Eli Lilly and Company, Hoffman-La Roche, and Bristol-Myers Squibb.